DWJ1622
Phase 1Small molecule
Daewoong Pharmaceutical Co. LTD.DWJ1622 is one of 72 small molecule programs targeting Fasting Conditions. It is currently in Phase 1.
2
Indications
2
Total Trials
2
Active Trials
71
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
114 competitors in Tics
#DrugCompanyPhaseTrials
1Sodium Valproate
AstraZenecaPhase 3
Priftin
SanofiPhase 2
Nydrazid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 2
Duvyzat
ItalfarmacoPhase 2
Dilaudid
RRhodes Pharmaceuticals, L.P.
Phase 2
CAB LA
GSKPhase 2
Aciphex
Akero TherapeuticsPhase 1
Invokana
WWim Janssens
Phase 1
Tylenol
KKenvue Brands
Phase 1
Rifampicin
Boehringer IngelheimPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DWJ1622. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details